The comparison of the efficacy of four different therapeutic regimens against Hlicobacter pylori infection in End Stage Renal Disease patients.
Phase 4
- Conditions
- Helicobacter pylori infection.Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
- Registration Number
- IRCT2015081123591N1
- Lead Sponsor
- Vice Chancellor for research of Golestan university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
All ESRD patients with confirmed H.pylori infection using Endoscopic gasterodeodenoscopy with complete consciousness of patient about research.
Exclusion criteria: Pregnancy, liver failure, patient with active cancer, recent using of Proton pomp inhibitors, Non steroidal anti inflammatory drugs, bismuth and antibiotics during last four weeks, history of alcohol abuse, cigarette smoking and any drug reactions.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori. Timepoint: 4 weeks after finishing of treatment course. Method of measurement: Patients swallow urea labelled with an uncommon isotope, either radioactive carbon-14 or non-radioactive carbon-13. In the subsequent 10–30 minutes, the detection of isotope-labelled carbon dioxide in exhaled breath indicates that the urea was split; this indicates that urease (the enzyme that H. pylori uses to metabolize urea) is present in the stomach, and hence that H. pylori bacteria are present.
- Secondary Outcome Measures
Name Time Method -. Timepoint: -. Method of measurement: -.